Continuing Education Activity

Mixed urinary incontinence (MUI) is a condition characterized by the involuntary leakage of urine, encompassing symptoms of both stress and urge incontinence. Stress incontinence involves urine leakage triggered by physical exertion or increased intraabdominal pressure (eg, coughing, sneezing, or exercising). Urge incontinence, on the other hand, is marked by a sudden, intense need to urinate, followed by involuntary urine loss. MUI is particularly prevalent in women older than 65, affecting >37% of older female patients, and often necessitates significant lifestyle changes due to its impact on both physical and psychosocial well-being.

The condition can lead to various health issues, including skin infections, increased risk of falls, and significant psychological distress. Quality of life is often substantially diminished, with patients experiencing depression, anxiety, social isolation, and sexual dysfunction. The burden of MUI extends beyond the patients themselves, significantly affecting family caregivers and nursing facilities, with up to 10% of nursing home admissions in the United States attributed solely to urinary incontinence.

Diagnosis of MUI typically involves a detailed clinical history and simple office tests, including urinalysis, postvoid residual urine volume measurement, and pelvic examinations. Treatment options range from conservative approaches (eg, lifestyle modifications and pelvic floor exercises) to more invasive interventions for cases unresponsive to initial treatments. Effective management of MUI often requires a collaborative effort from an interprofessional healthcare team to improve patient outcomes and quality of life. This activity for healthcare professionals is designed to enhance the learner's competence in identifying mixed urinary incontinence, implementing appropriate management, and collaborating with interprofessional team members to improve patient outcomes.

Objectives:

• Identify key risk factors associated with mixed urinary incontinence.
• Differentiate mixed urinary incontinence from other differential diagnoses.
• Implement evidence-based interventions for managing mixed urinary incontinence.
• Coordinate with the interprofessional team to enhance care for patients affected by mixed urinary incontinence.

Introduction

Urinary incontinence is the involuntary leakage of urine, causing symptoms of wide-ranging severity and often significantly affecting patients' quality of life. The International Urogynecological Association (IUGA), the International Incontinence Society (ICS), and the American Urological Association (AUA) have divided urinary incontinence into 3 main classifications.[1][2] See StatPearls' companion reference, "Urinary Incontinence," for more information.[2] 

Stress incontinence is the involuntary loss of urine with increased intraabdominal pressure or physical exertion (eg, coughing, sneezing, jumping, lifting, laughing, straining, exercising).[3] Urge incontinence is the involuntary loss of urine preceded by a sudden and severe desire to pass urine.[4] See StatPearls' companion references, "Urge Incontinence" and "Stress Incontinence," for more detailed information on these respective conditions.[4][3] Mixed urinary incontinence (MUI) is a combination of stress and urge incontinence and may take on the pathophysiology of both.[2][5] MUI is particularly prevalent in women older than 65, affecting >37% of older female patients, and often necessitates significant lifestyle changes due to its impact on both physical and psychosocial well-being.[6][7][8] 

Although incontinence is not itself a terminal disease, a meta-analysis of 6 studies with a total of 1,656 individuals indicated that urinary incontinence contributes to overall mortality, at least in nursing home residents, where it increases the death rate by 20%.[9] However, urinary incontinence more often affects other aspects of the patient's health and quality of life. Health conditions associated with MUI include skin, perineal, and vaginal infections (eg, cellulitis and yeast), as well as an increased risk of falls and fractures from excess trips to the bathroom.[10][11] The incidence of falls in postmenopausal women with urinary urgency and urge incontinence is twice that of comparatively aged women without such urinary symptoms.[11][12] Additionally, quality of life is significantly affected as incontinence causes depression, anxiety, embarrassment, limitation of social interactions, increased isolation, work issues, sleep deprivation due to nocturia, and loss of self-esteem in those affected.[13][14][15][16][17] Sexual dysfunction is also common in incontinent patients, as up to 33% will have coital incontinence (ie, leakage during sexual activity). Consequently, the fear of coital incontinence tremendously affects sexual enjoyment in many patients.[18][19][20][21][22][23] MUI also places a substantially increased burden on family caregivers as well as nursing facilities.[24][25][26] Up to 10% of all nursing home admissions in the United States are solely due to urinary incontinence.[27] 

A careful clinical history is usually sufficient to identify the type of the patient's incontinence; however, noninvasive diagnostic evaluations, including urinalysis, postvoid residual urine volume, and a pelvic examination in women, should be utilized to help clarify the clinical characteristics and etiology.[28][29][30][31][32][33] Many behavioral, medical, and surgical techniques are available to improve lifestyles due to incontinence.[1][34] The initial treatment for incontinence typically begins with a conservative lifestyle approach and various nonsurgical measures, including Kegel exercises, caffeine avoidance, vaginal estrogen in women, physical therapy, and oral medications.[35][36] For conditions unresponsive to such conservative therapies, consideration of more invasive therapies may be indicated. 

Etiology

MUI is associated with advanced levels of female pelvic organ prolapse, which has been demonstrated from the finding that restoration of normal anatomy through vaginal pelvic reconstructive surgery for prolapse cured >50% of the patients who had concomitant MUI.[6] Pelvic organ prolapse leads to bladder outlet obstruction, which causes detrusor muscle neuropathy from ischemia and hypoxia from inappropriate overstretching.[37] This bladder overstretching leads to a heightened reaction to neurotransmitters while the number of contracting muscle fibers decreases, resulting in reduced cellular propagation of membrane potential changes and loss of detrusor muscle fiber synchronization.[38][39][40] The net result is an irritable and overactive bladder.

Incontinence occurs when the endopelvic fascia weakens, which causes urethral distortion, malposition, hypermobility, decreased urethral tension, support, and loss of normal bladder positioning, which collectively results in involuntary urine loss.[6][41] Various incontinence subtypes have been identified, including genitourinary (eg, fistula, infectious, congenital, overflow) and nongenitourinary (eg, functional, environmental, pharmacological, and metabolic). Of these, the most clinically significant would be overflow and functional incontinence. Overflow is the involuntary urinary leakage caused by an overdistended bladder, usually due to bladder outlet obstruction or reduced detrusor contractility from spinal cord injuries, multiple sclerosis, or diabetes; functional incontinence is leakage from environmental, logistical, or physical barriers to reaching the toilet.[2] 

Mixed Urinary Incontinence Risk Factors

Factors that increase the risk of a patient developing MUI include the following:

• Advanced age 
• Comorbidities (eg, depression, diabetes, stroke, fecal incontinence, atrophic vaginitis, cognitive impairment, history of recurrent UTIs, multiple sclerosis, hydrocephalus, and childhood enuresis)
• Ectopic ureters
• Exercise, especially high-impact (eg, running and jumping)
• Family history 
• Interstitial cystitis
• Multiparity
• Neuropathy
• Nursing home residence
• Obesity
• Pelvic radiation history
• Prior pelvic surgery (eg, transurethral resection of the prostate, hysterectomy)
• Smoking [23][42][43][44][45][46][47]

Epidemiology

Due to embarrassment, many patients with urinary incontinence fail to report symptoms, so the actual prevalence is likely to be far greater than reported.[23] Urinary incontinence affects 25% to 45% of all adult American women.[2] More than 25% of teenage and college-aged female athletes experience incontinence, with more than 90% withholding incontinence information from their primary care clinicians.

Among homebound older individuals, the incidence of incontinence is 53%.[2] In nursing homes, approximately 6% of all admissions are due to urinary incontinence, but the prevalence of urinary leakage in nursing home residents is estimated to be ≥50%.[48] Urinary incontinence in women is twice the rate of men, and over 33% of women with significant pelvic organ prolapse will also have MUI.[48][49]

The cost to treat urinary incontinence, medically or surgically, is well over $10 billion annually. Urinary incontinence, particularly mixed type, is an issue across all age groups.[50] The worldwide incidence of incontinence is approximately 423 million individuals aged 20 and older.[51] The following are the estimated prevalences for the different types of chronic urinary incontinence:

• Functional urinary incontinence: uncertain
• MUI: 20% to 30%
• Overflow urinary incontinence: 5% of those with chronic incontinence
• Stress urinary incontinence: 24% to 45% of females older than 30 years
• Urge urinary incontinence

  • Women aged 40 to 44 years: 9%
  • Men older than 75 years: 42% 
  • Women older than 75 years: 31% [52]

Pathophysiology

The underlying mechanisms leading to MUI comprise stress and urge incontinence. The pathophysiology of stress incontinence is primarily pelvic floor weakness, prolapse, or loss of the normal urethrovesical angle.[3] The posterior urethrovesical angle with straining should usually be less than 120 degrees.[3] Stress incontinence also includes intrinsic sphincter deficiency, where there are deficiencies in the closure of the urinary sphincter.[3] 

The pathophysiology of urge incontinence is uninhibited bladder contractions caused by the loss of neurologic control of bladder contractions.[4] These unstoppable bladder contractions can be triggered or stimulated by a change in body position, from supine to upright, or with sensory stimulation (eg, running water, hand washing, cold weather).[4] Uninhibited bladder contractions are caused by detrusor muscle overactivity, poor detrusor compliance, loss of neurologic control of bladder contractions, and bladder hypersensitivity.[4] Underlying etiologies may include neurologic disorders, pelvic radiation, changes in the microbiome of the bladder, prolonged Foley catheterization, or idiopathic.[4][53][54][55][56][57] See StatPearls' companion references, "Urge Incontinence" and "Stress Incontinence," for more detailed information on these respective conditions.

History and Physical

Clinical History

A thorough history needs to be obtained to help diagnose MUI. The clinician should initiate the conversation by inquiring about symptoms directly since the patient may be too embarrassed to discuss increased frequency, urgency, or dysuria symptoms.[2] Clinical features include hesitancy, slow stream, straining to void, incomplete emptying, or wetting pads or clothes. Obtaining past surgical and obstetrical history is also essential to help diagnose the type of incontinence.[2] Details about the nature of incontinence symptoms are needed for diagnosis, including when the problem started, duration, precipitating events, voiding frequency, leakage volume, pad usage, nocturia, and fluid intake.[2][4] Caffeine intake should also be documented as caffeine can worsen urgency symptoms.[2][4] 

Many assessment questionnaires are available to help quantify the symptomatic effects on daily living. Comorbidities and confounding factors should also be explored. Medications that affect urinary incontinence should be reviewed, particularly cholinergic drugs and diuretics. In women, the effects of decreased estrogen levels during perimenopause or postmenopause should also be discussed, and the potential benefits of vaginal estrogen cream.[58] A 24-hour voiding diary prepared by the patient is helpful for objectively quantifying incontinence and helping evaluate the condition.[31][32][33][59] A voiding diary comprising 3 days is preferred, but even a 24-hour voiding diary from 1 day can be helpful.

Physical Examination

Findings of both stress and urge incontinence are consistent with MUI. The physical exam of patients with MUI should focus on the abdominal and pelvic areas. A large panniculus, prior surgical incisions, and suprapubic muscle tone should be noted. The patient should be examined with a full and empty bladder in standing and supine positions.[2] In women, the grade of uterine, vaginal prolapse should be assessed along with any apparent stress urinary incontinence with coughing.[1] A rectal examination should also be performed to evaluate rectal sphincter tone and prostate size in men.

A cough stress test is typically used to assess stress incontinence. For this test, 250 to 300 mL of fluid is instilled into the bladder using a catheter. The catheter is removed, and the patient is asked to cough. If no leakage is observed in the supine position, the patient is asked to stand, and the test is repeated.[59] The cough stress test is considered a fairly definitive test for stress incontinence, with a positive predictive value of 78% to 97%.[60][61] A negative test is less reliable as the bladder may have insufficient volume, or the patient may be inhibiting leakage due to anxiety or embarrassment.

Evaluation

Initial Urinary Incontinence Diagnostic Testing

The following simple office incontinence evaluations should be initially utilized to help differentiate the different types of urinary incontinence.[28][29][30][31][32][33]

• Urinalysis and culture: Urine testing should be performed to exclude an infectious process (eg, acute cystitis).

• Postvoid residual urine volume: This assessment is recommended to check for overflow incontinence and incomplete bladder emptying.[28][62] About 20% of women with overactive bladder symptoms will have elevated postvoid residual urine volumes.[63] Risk factors of high postvoid residuals include individuals 55 years and older, previous surgery for incontinence, multiple and more severe urinary symptoms, multiple sclerosis, vaginal prolapse, and more than 2 previous vaginal deliveries.[63] 

• A 24-hour voiding diary: Tracking the frequency and volume of incontinence helps evaluate the severity and nature of the patient's leakage, particularly the urgency component.[29][31][32][33][64][65][66][67]

• Cough stress test: A positive cough stress test in both the sitting and supine positions is highly diagnostic for stress incontinence.[29][68]

• Pelvic examination: Vaginal prolapse may mask or decrease incontinence symptoms; therefore, areas of prolapse surrounding the urethra should be corrected (ie, elevated to the correct anatomical position) followed by assessment of incontinence with stress (eg, cough stress test).[29] The levator ani muscle should also be examined for strength.[29]

• Q-tip test: This assessment is performed with a cotton-tipped swab placed gently into the urethra to check for mobility. A displacement of the urethral angle of at least 30 degrees with Valsalva is suggestive of urethral hypermobility.[29][30][69][70]

• Neurological evaluation: All patients with urinary incontinence should undergo a neurologic assessment to exclude neurogenic causes of their incontinence.

• Ultrasound: Transperineal/translabial ultrasound has proven useful in the evaluation of women with MUI with a significant stress component.[71] Ultrasound demonstrates the posterior urethral angle and the degree of urethral inclination.[71][72] Ultrasound imaging also allows visualization of the degree of bladder neck descent and the distance between the pubic bone, urethra, and bladder neck.[71][72] For example, female patients with MUI with an urge predominance tended to have thicker bladder walls, while those women with equivalent urge and stress components demonstrated greater bladder neck descent.[72] Additionally, ultrasound is substantially quicker and much better tolerated by patients than urodynamics.[71]

• Additional evaluation procedures: Further incontinence assessment and exclusion of differential diagnoses can be achieved with additional studies, including cystoscopy, urodynamics, and video-urodynamic testing.[29]

Specialized Urodynamic Testing

For more complex or atypical presentations of incontinence, the patient may require urodynamic testing for further evaluation by a urology specialist.[73] Many experts consider MUI alone as an indication for urodynamics testing.[73][71] Urodynamic confirmation of MUI would demonstrate both stress incontinence and detrusor overactivity.[71] Cough-induced detrusor overactivity needs to be differentiated from true mixed incontinence.[74] Other indications for multi-channel urodynamics include: [73][75][76]

• Abnormal office cystometric testing
• Preoperative assessment before invasive surgical incontinence procedures, especially complex or high-risk cases 
• Continuous or unpredictable leakage
• Diagnostic uncertainty, even after the initial history and physical
• History of previous radical pelvic surgery
• Incontinence treatment failures
• Neurological disease or symptomatology
• Patient symptoms do not correlate with their physical findings
• Pelvic organ prolapse
• Pelvic radiation
• Previous failed incontinence surgery 

Treatment / Management

Conservative Therapy

The initial treatment for incontinence typically begins with conservative, nonsurgical measures, including bladder training, biofeedback, Kegel exercises, dietary modifications (eg, avoidance of excess caffeine intake), acupuncture, electroacupuncture, vaginal estrogen in postmenopausal women, weight loss, and physical therapy.[35][77][78][79][80][81][82][83][84][85][86][87] The treatment of MUI should always begin with the least invasive management option to determine if the symptoms become tolerable or minimized by the patient. If invasive procedures are avoided, the patient may be satisfied with improved rather than complete continence, particularly if the patient has a high surgical risk.

Bladder training

Bladder training is generally the first step in management.[71][88] Bladder training typically works best in conjunction with regular Kegel exercises and limiting caffeine intake. It typically requires 6 to 12 weeks to be effective. See StatPearls' companion reference, "Kegel Exercises," for more information. Standard patient instructions for bladder training typically include the following protocol:

• Void first thing in the morning.
• Try to wait a minimal amount of time before voiding. Then, gradually increase this time.
• Keep a voiding diary to establish a urination pattern; add 10 or 15 minutes to typical urination times.
• Add another 10 or 15 minutes when this regimen becomes comfortable and manageable. Continue to add 10 to 15 minutes until an interval of 3 to 4 hours between daytime voids is reached.
• Wait at least 5 minutes to void after the urge to void is noted; then, gradually increase the amount of time by an additional 5 to 10 minutes. 
• If the urge to void cannot be controlled, void and return to the previous regimen.
• Maintain the voiding diary to track progress.[88][89]

Bladder training typically works best when combined with regular Kegel exercises and limiting caffeine intake. Bladder training typically requires 6 to 12 weeks to be effective. Scheduled voiding may also be used.

Knack tutorial

The Knack tutorial is a self-administered story-based video program that helps train patients to anticipate high-risk urinary leakage situations.[90] They are then taught to perform preemptive pelvic floor muscle contractions at the optimal time to eliminate leakage.[90][91] Physiologically, the knack technique reduces stress incontinence by reducing bladder excitability and improving urethral closing pressure.[90][92][93][94] Detrusor contractions are suppressed; therefore, less urgency and urge incontinence are present.[90][94][95][96][97] In a randomized controlled trial, 71% of patients reported significant improvement in their incontinence with this technique compared to just 21% using diet and exercise alone.[90] The Knack tutorial video for incontinence training is available for free viewing on YouTube.

Ancillary conservative therapies

Several noninvasive treatments have been developed to facilitate pelvic floor muscle and bladder training, including vaginal cones, intravaginal biofeedback, percutaneous tibial nerve stimulation, and pelvic floor muscle training via direct electrical vaginal activation or with extracorporeal magnetic innervation therapy.[78][79][98][99][100][101][102][103][104][105] While helpful in some patients, their benefit may not be substantially better overall than properly performed bladder training programs, Kegel exercises, and pelvic floor muscle training.[106] Combination treatments typically provide substantially better results than monotherapies.[79][107] Particularly effective treatments in comparative randomized controlled studies were bladder training with electrical stimulation, with or without biofeedback, and percutaneous tibial nerve stimulation.[79][108][109]

Initially, conservative treatments are primarily utilized for symptom relief, which for most patients involves reduction of incontinence frequency and urgency.[35] Urgency symptoms and urge incontinence can be treated pharmacologically with a variety of medications.[4][110][111][112][113] Conservative measures for MUI have the disadvantage that the improvement noted with treatment usually does not last, and most of the therapies require hospitalization or specialized clinics.[79] Resistant cases may require tibial nerve stimulation, botulinum A toxin detrusor injections, or sacral neuromodulation therapy.[4] External catheters, condom catheters for men and low-pressure vacuum wick units for women, can be used for nocturnal enuresis and overnight incontinence management but will not cure the underlying problem.[114][115][116][117][118][119]

Stress incontinence is typically treated surgically (eg, sling, repair of prolapse, or cystocele repair); however, for some patients, a pessary may provide satisfactory continence less invasively.[3][106] A pessary supports the urethra and bladder neck, increases urethral length, and gently compresses the urethra against the pubic bone, increasing urethral resistance and reducing or eliminating stress incontinence.[120][121][122][123][124][125][126] When properly sized and fitted, no discomfort or unpleasant sensation is typically noted; however, pessaries must be periodically removed and cleaned with soap and water. Side effects of using a pessary include irritation to the vaginal mucosa with subsequent pain and bleeding. Pessaries may also increase the risk of vaginal infections or interfere with bowel movements. Since pessaries are minimally invasive and their effects can be easily reversed by simple removal, pessaries are a reasonable clinical option, especially when avoiding or delaying surgery is desirable. Proper sizing and fitting are critical.

Behavioral therapies

Treatment approaches that assist in changing behaviors that exacerbate MUI include:

• Biofeedback
• Bladder retraining (eg, timed voiding)
• Dietary changes, including avoidance of alcohol, coffee, tea, caffeine, soda, chocolates, or methylxanthines
• Electrostimulation
• Extracorporeal magnetic innervation therapy
• Pelvic floor physical therapy [127]

Pharmacologic agents

In patients who are unresponsive to nonpharmacologic therapies, medications that may improve symptoms include: 

• Alpha-adrenergics (eg, mirabegron, vibegron)
• Anticholinergics (eg, oxybutynin, solifenacin, tolterodine, and trospium)
• Calcium channel blockers (amlodipine, nifedipine, verapamil).
• Estrogen (in females)
• Selective serotonin and norepinephrine reuptake inhibitors (eg, duloxetine)
• Tricyclic antidepressants (eg, imipramine) [128][77][129][130]

Duloxetine has good evidence in studies that urinary stress incontinence is improved with the medication by increasing urethral closing pressure, while imipramine appears to have only minimal effect.[131][132][133][134][135][136] In Europe, duloxetine is approved for female stress incontinence, where it has shown efficacy in studies.[133][128][137] Still, consideration must also be given to the significant adverse side effects involving mental health issues, increased suicide rates, and other issues.[133][137][138][139] Nocturia not relieved by the above measures may require separate evaluation and treatment.[140] Nocturnal polyuria, for example, may require desmopressin.[140] Changing the administration timing of furosemide to 6 hours before bedtime may also be helpful.[140] See StatPearls' companion reference, "Nocturia," for more detailed information. 

If standard pharmacological agents are inadequate, alternative therapies for intractable bladder overactivity include tibial nerve stimulation, botulinum A toxin detrusor injections, and sacral neuromodulation therapy may also be utilized.[4][141] See StatPearls' companion references, "Urge Incontinence" and "Sacral Neuromodulation," for more detailed information.[4][141] 

Indications for Specialist Referral

Primary care clinicians typically treat MUI initially using noninvasive therapies, including behavioral techniques or pharmacologic agents, when urinary retention, overflow, and UTIs have been excluded. However, referral to a urogynecologist or urologist is recommended, particularly when surgical intervention appears necessary or conservative treatments fail. Indications for referral to a specialist include: [142]

• Abdominal or pelvic pain
• Comorbidities (eg, cerebral palsy, multiple sclerosis, spinal cord injury, Parkinson disease)
• Hematuria without evidence of an infection
• Nerve stimulation therapy
• Neurogenic bladder, primarily if associated with new symptoms
• Pelvic organ prolapse
• Prior failed incontinence surgery
• Recurrent urinary tract infections
• Sacral neuromodulation therapy
• Surgical intervention is being considered when a patient is not satisfied even when the urge component of the MUI is cured or well-controlled
• Suspected or diagnosed vesicovaginal fistula
• Symptomatic pelvic organ prolapse
• Uncertain diagnosis
• Underlying neurologic condition
• Unsuccessful medical therapy
• Unusually "heavy" stress urinary incontinence (ie, multiple pads per day)
• Urinary retention or overflow
• Urodynamics required
• Voiding dysfunction (eg, elevated postvoid residual) [142]

Surgical Therapy

Surgery provides the best overall cure for MUI when significant prolapse with bothersome stress urinary incontinence and pelvic pressure symptoms are present. However, surgery deals only with the stress incontinence component; the urgency portion must be treated separately, usually with pharmacological agents. Furthermore, controlling the overactive bladder component before surgery and ensuring patients fully understand the benefits and limitations of surgical procedures before the operation may help improve outcomes and patient satisfaction. Surgery aims to restore and reinforce the paraurethral connective tissue, the pubourethral ligaments, and the suburethral vaginal hammock at the mid-urethra level. Pelvic organ prolapse, rectoceles, and cystoceles may also require surgical repair.[143][144][145]

The standard surgical therapy for stress urinary incontinence is a sling procedure (eg, mid-urethral slings). However, several abdominal and vaginal surgical options are available, including Marshall Marchetti Krantz, Burch, paravaginal repairs, laparoscopic procedures, modified Pereyra procedures, Stamey, Raz, and other sling surgeries. Most of these have similar cure rates.[146][147] See StatPearls' companion references, "Stress Incontinence" and "Pubovaginal Sling," for more detailed information on these respective sling procedures.[3][146] See StatPearls' companion references, "Cystocele," "Rectocele," "Pelvic Organ Prolapse," and "Uterine Prolapse," for more detailed information on these respective topics.[143][144][145][148]

More than 50% of female patients who have significant pelvic organ prolapse can see significant improvement in their incontinence symptoms from surgical repair of the prolapse with or without a surgical sling. Appropriate anticholinergic therapy can then help control remaining bladder overactivity.[6][149][150][151] Perurethral bulking agents, adjustable continence therapy periurethral balloons, and artificial sphincters may also be used for stress incontinence.[3] While slings are generally a good option for isolated urinary stress incontinence, patients with MUI who have significant urinary urgency may not be satisfied with the postoperative results.[152] Predictors of poor patient satisfaction with stress incontinence surgery include significant preoperative overactive bladder symptoms, prolonged duration of incontinence, >9.5 years, requiring preoperative anticholinergic medications, and diabetes, as well as unrealistic patient expectations.[152] 

Adjustable continence therapy devices

Adjustable continence therapy devices consist of implantable periurethral balloons placed at the level of the bladder neck.[153][154] A special trocar creates a tunnel through which the balloons are placed.[153][154] Each balloon has an adjustment port placed in the scrotum or under the skin for percutaneous access.[153][154] Adjustments can easily be made in the office or clinic. An open perineal approach has also been described for patients where the usual trocar tunneling procedure is unsafe or unsuitable.[154][155]

Overall results are excellent, with continence rates consistently reported as over 50% in properly selected patients.[153][154][155][156][157][158] The surgery is simpler and less expensive than artificial sphincters. While the device creates a static degree of urethral compression, it is adjustable so the degree of urethral obstruction can be modified. Adjustable continence therapy devices are a less invasive and simpler surgical option for many male and female patients, with a success rate comparable to the artificial urinary sphincter.[154][159][160][161][162][163] 

Adjustable continence therapy devices constitute a significantly underutilized therapeutic option for patients with stress incontinence as they offer a significantly less invasive option to artificial urinary sphincters.[154][158] While effective in both sexes, these devices are only FDA-approved for men in the United States.[154][164][165] See StatPearls' companion reference, "Artificial Urinary Sphincters and Adjustable Dual-Balloon Continence Therapy in Men," for more detailed information on these devices.[154]

Artificial urinary sphincters

Artificial urinary sphincters are devices FDA-approved for use in both men and women with significant incontinence not amenable to other treatments. The usual indication for an artificial sphincter is neurogenic stress incontinence and persistent incontinence after prior surgery.[166] Artificial sphincters are essentially a treatment of last resort when lesser invasive options have failed. In this complex group of patients, outcomes with the artificial sphincter are reportedly quite good, even in women older than 75 with otherwise intractable stress incontinence.[167][168][169][170][171][172] Unlike other surgical corrective procedures for stress incontinence, an artificial sphincter can uniquely adjust and lower urethral resistance during voiding while maintaining high resistance and continence, making it particularly suitable for patients with significant detrusor weakness.[166] 

Complications of artificial sphincters include atrophy, erosion, device failure, scarring, and infection.[173] Due to cost and technical difficulty in implantation, artificial sphincters are a significantly underutilized treatment modality. Recent innovations in implantation using laparoscopic and robotic techniques have reduced postoperative complications, and worldwide usage is increasing.[173][174][175] Further improvements in the device and implantation techniques should help increase its utilization.[176] See StatPearls' companion reference, "Artificial Urinary Sphincters and Adjustable Dual-Balloon Continence Therapy in Men," for more detailed information.[154]

Intrinsic sphincter deficiency is due to the loss of urethral muscle tone from neuromuscular damage (eg, repeated incontinence or pelvic surgeries). Intrinsic sphincter deficiency may sometimes be associated with urethral hypermobility. Leakage tends to be severe and may be continuous. Even minimal increases in abdominal pressure can cause significant incontinence. Treatment is similar to standard stress incontinence therapies, but the condition is more challenging to treat, and surgical outcomes are generally not as good. Midurethral slings are usually the preferred surgical option. Still, other sling types, urethral bulking agents, adjustable continence therapy device periurethral balloons, and artificial sphincters may also be considered for both male and female incontinence patients.[156][159][163][177][178][179][180] Artificial sphincters tend to provide a better functional result in female patients with intrinsic sphincter deficiency than other surgeries, but they also have a higher rate of intraoperative and postoperative complications, take more operating room time to implant, are more prone to device failures, and require a longer inpatient hospital stay.[181] 

Differential Diagnosis

Differential diagnoses that should be considered include:

• Acute or chronic cystitis
• Benign prostatic hyperplasia 
• Cough-induced detrusor overactivity
• Cystocele, rectocele
• Interstitial cystitis
• Multiple sclerosis
• Neurogenic bladder
• Prostatitis
• Radiation cystitis
• Spinal cord abscess
• Spinal cord neoplasms
• Spinal cord trauma
• Urethral strictures
• Urge incontinence
• Urinary obstruction
• Urinary tract infections in males
• Uterine prolapse
• Vaginitis

Prognosis

If a patient desires stress urinary incontinence to be cured with no leakage, proper informed consent for surgical treatment should be discussed and explained to the patient. Counseling regarding surgical success rates must be included. Abdominal and vaginal surgical approaches offer similar overall success rates of approximately 86% for cure, 7% for improvement, and a 7% failure rate.[147] A clinical cure, meaning no further incontinence, indicates that the patient will not need further postoperative treatment or urodynamic testing.

Clinical improvement with occasional intermittent incontinence or failed procedures may require urodynamic testing to differentiate stress versus urge incontinence or any other subtypes and variations. Behavioral or medical therapy may be necessary in refractory cases, with the possibility of another reoperation as a last resort. Newer surgical approaches (eg, periurethral bulking agents, adjustable continence device therapy, and artificial sphincters) can successfully relieve stress incontinence symptoms in both men and women who have failed other treatments.[3] Sacral neuromodulation, botulinum A toxin detrusor injections, and tibial nerve stimulation can often help patients with otherwise intractable urgency and overactive bladder symptoms refractory to standard pharmacological therapy.[4][141]

Complications

The risk of surgical treatment pertinent to stress urinary incontinence should also be documented and explained to the patient. Risks include the following:[147]

• Bleeding
• Infection
• Injury to the genitourinary or gastrointestinal tract
• Persistent or recurrent urinary incontinence or prolapse
• Postop dyspareunia 
• Urethral erosion [147]

Postoperative and Rehabilitation Care

Postoperative patients may require prolonged catheterization either with a urethral or suprapubic catheter. The postvoid residual urine should be <100 mL. Any voiding dysfunction after catheter removal usually resolves spontaneously within a few days to weeks. Coital activity should be avoided at least 6 weeks following surgery to prevent disruption of the surgical site until healing is complete. The patient also should be told no heavy lifting over 25 lbs to avoid increasing intraabdominal pressure that may result in treatment failure with recurrent prolapse and incontinence.

Deterrence and Patient Education

Education involving the patient, the public in general, and healthcare clinicians is necessary to provide the best patient outcomes according to evidence-based medicine. Websites of reliable sources that offer free patient education and informational resources on incontinence include:

1. The American College of Obstetrics and Gynecology Website: [acog.org/womens-health/faqs/urinary-incontinence]
2. Patient education from the American Urological Association and the Urology Care Foundation Website: [urologyhealth.org/urinary-incontinence]
3. National Association for Continence (NAFC) Website: [nafc.org/mixed-incontinence] Phone: 800-252-3337
4. The Simon Foundation for Continence Website: [simonfoundation.org] Phone: 800-237-4666
5. European Association of Urology Patient Education on Incontinence Website: [urinary-incontinence]
6. Continence Worldwide (Continence patient educational resources outside the United States) Website: [www.ics.org/public]
7. International Urogynecological Association (IUGA) Website: [yourpelvicfloor.org]
8. United Kingdom National Health Services Patient Information Website: [nhs.uk/conditions/urinary-incontinence] 
9. Continence Foundation of Australia Website: [continence.org.au/urinary-incontinence]

Pearls and Other Issues

Key facts to keep in mind with urinary incontinence include:

• Giving patients realistic treatment expectations right at the beginning can help them accept a less-than-perfect outcome.
• Treat the most bothersome symptoms first, which are usually urgent, frequent, and amenable to pharmacological treatments.
• While post-void residual determinations are not required before initiating clinical treatment, many experts suggest checking this to avoid overlooking possible overflow incontinence.
• A 24-hour voiding diary, including void frequency and volume, can be very helpful in sorting out a complex incontinence problem.[65][66]
• Consider using a pessary as it can immediately relieve stress incontinence symptoms. If unsatisfactory for any reason, it can be removed.
• Adjustable continence devices and artificial sphincters are underutilized procedures that should be discussed and offered to appropriate patients, especially women.
• A disposable self-inserted intravaginal pessary is undergoing clinical trials. Over 87% of female users have reported a reduction in leakage by at least 50% with no severe adverse effects.[182]
• Consider using low-pressure external vacuum wick incontinence units for nocturnal enuresis and nighttime incontinence management in women.[118][119] While it does not cure incontinence, it minimizes side effects, keeps the skin dry, and helps manage wetness at least overnight. A male pad for this device is now available, or a properly fitted and secured condom catheter can be used for men.[118][119][183] 

Enhancing Healthcare Team Outcomes

Urinary incontinence is a salient issue in any primary care clinician's practice, necessitating a thorough history and workup to establish an accurate differential diagnosis before discussing treatment strategies. Clinicians must inform patients of all available treatment options, ensuring patients understand that not all treatments completely cure symptoms. Success should be defined as a reduction in severity that satisfies the patient's quality of life. Clear communication of reasonable expectations and potential reasons for unmet expectations is crucial. Ethically, all health professionals must advise patients of the least invasive treatment options, such as behavioral modification or medications, before considering surgical plans. An interprofessional approach involving physicians, advanced practitioners, nurses, pharmacists, and other health professionals, coupled with excellent communication and consistent messaging, is essential when urogynecologists, urologists, or other specialists are involved in managing mixed urinary incontinence. This collaborative effort enhances patient-centered care, outcomes, patient safety, and overall team performance.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

ACOG Practice Bulletin No. 155: Urinary Incontinence in Women. Obstet Gynecol. 2015 Nov;126(5):e66-e81. [PubMed: 26488524]

2.

Leslie SW, Tran LN, Puckett Y. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 11, 2024. Urinary Incontinence. [PubMed: 32644521]

3.

Lugo T, Leslie SW, Mikes BA, Riggs J. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 31, 2024. Stress Urinary Incontinence. [PubMed: 30969591]

4.

Nandy S, Ranganathan S. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Sep 19, 2022. Urge Incontinence. [PubMed: 33085319]

5.

Irwin DE, Milsom I, Chancellor MB, Kopp Z, Guan Z. Dynamic progression of overactive bladder and urinary incontinence symptoms: a systematic review. Eur Urol. 2010 Oct;58(4):532-43. [PubMed: 20573443]

6.

Lo TS, Uy-Patrimonio MC, Kao CC, Chua S, Huang TX, Wu MP. Urodynamics mixed type urinary incontinence with advanced pelvic organ prolapse, management and outcomes. Sci Rep. 2020 Feb 06;10(1):1944. [PMC free article: PMC7005146] [PubMed: 32029796]

7.

Erekson EA, Cong X, Townsend MK, Ciarleglio MM. Ten-Year Prevalence and Incidence of Urinary Incontinence in Older Women: A Longitudinal Analysis of the Health and Retirement Study. J Am Geriatr Soc. 2016 Jun;64(6):1274-80. [PMC free article: PMC4916851] [PubMed: 27321606]

8.

AlQuaiz AM, Kazi A, AlYousefi N, Alwatban L, AlHabib Y, Turkistani I. Urinary Incontinence Affects the Quality of Life and Increases Psychological Distress and Low Self-Esteem. Healthcare (Basel). 2023 Jun 15;11(12) [PMC free article: PMC10297870] [PubMed: 37372891]

9.

Huang P, Luo K, Wang C, Guo D, Wang S, Jiang Y, Huang W, Zhang W, Ding M, Wang J. Urinary Incontinence Is Associated With Increased All-Cause Mortality in Older Nursing Home Residents: A Meta-Analysis. J Nurs Scholarsh. 2021 Sep;53(5):561-567. [PubMed: 34021695]

10.

Brown JS, Vittinghoff E, Wyman JF, Stone KL, Nevitt MC, Ensrud KE, Grady D. Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc. 2000 Jul;48(7):721-5. [PubMed: 10894308]

11.

Gibson W, Hunter KF, Camicioli R, Booth J, Skelton DA, Dumoulin C, Paul L, Wagg A. The association between lower urinary tract symptoms and falls: Forming a theoretical model for a research agenda. Neurourol Urodyn. 2018 Jan;37(1):501-509. [PubMed: 28471525]

12.

Schluter PJ, Askew DA, Jamieson HA, Arnold EP. Urinary and fecal incontinence are independently associated with falls risk among older women and men with complex needs: A national population study. Neurourol Urodyn. 2020 Mar;39(3):945-953. [PubMed: 32017231]

13.

Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008 Jun;101(11):1388-95. [PubMed: 18454794]

14.

Yip SK, Cardozo L. Psychological morbidity and female urinary incontinence. Best Pract Res Clin Obstet Gynaecol. 2007 Apr;21(2):321-9. [PubMed: 17207664]

15.

Coyne KS, Wein AJ, Tubaro A, Sexton CC, Thompson CL, Kopp ZS, Aiyer LP. The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int. 2009 Apr;103 Suppl 3:4-11. [PubMed: 19302497]

16.

Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care. 2000 Jul;6(11 Suppl):S574-9. [PubMed: 11183900]

17.

Dubeau CE, Simon SE, Morris JN. The effect of urinary incontinence on quality of life in older nursing home residents. J Am Geriatr Soc. 2006 Sep;54(9):1325-33. [PubMed: 16970638]

18.

Ratner ES, Erekson EA, Minkin MJ, Foran-Tuller KA. Sexual satisfaction in the elderly female population: A special focus on women with gynecologic pathology. Maturitas. 2011 Nov;70(3):210-5. [PMC free article: PMC3598121] [PubMed: 21943557]

19.

Barber MD, Visco AG, Wyman JF, Fantl JA, Bump RC., Continence Program for Women Research Group. Sexual function in women with urinary incontinence and pelvic organ prolapse. Obstet Gynecol. 2002 Feb;99(2):281-9. [PubMed: 11814510]

20.

Gray T, Li W, Campbell P, Jha S, Radley S. Evaluation of coital incontinence by electronic questionnaire: prevalence, associations and outcomes in women attending a urogynaecology clinic. Int Urogynecol J. 2018 Jul;29(7):969-978. [PubMed: 28620792]

21.

Munaganuru N, Van Den Eeden SK, Creasman J, Subak LL, Strano-Paul L, Huang AJ. Urine leakage during sexual activity among ethnically diverse, community-dwelling middle-aged and older women. Am J Obstet Gynecol. 2017 Oct;217(4):439.e1-439.e8. [PMC free article: PMC5614816] [PubMed: 28602772]

22.

Serati M, Salvatore S, Uccella S, Nappi RE, Bolis P. Female urinary incontinence during intercourse: a review on an understudied problem for women's sexuality. J Sex Med. 2009 Jan;6(1):40-8. [PubMed: 19170835]

23.

Abrar S, Mohsin R, Samad A. Female Urinary Incontinence: Frequency, Risk Factors, and Impact on the Quality of Life of Pregnant Pakistani Women. Pak J Med Sci. 2023 May-Jun;39(3):667-671. [PMC free article: PMC10214798] [PubMed: 37250566]

24.

Schumpf LF, Theill N, Scheiner DA, Fink D, Riese F, Betschart C. Urinary incontinence and its association with functional physical and cognitive health among female nursing home residents in Switzerland. BMC Geriatr. 2017 Jan 13;17(1):17. [PMC free article: PMC5237224] [PubMed: 28086759]

25.

Gotoh M, Matsukawa Y, Yoshikawa Y, Funahashi Y, Kato M, Hattori R. Impact of urinary incontinence on the psychological burden of family caregivers. Neurourol Urodyn. 2009;28(6):492-6. [PubMed: 19090589]

26.

Bektas Akpinar N, Unal N, Akpinar C. Urinary Incontinence in Older Adults: Impact on Caregiver Burden. J Gerontol Nurs. 2023 Apr;49(4):39-46. [PubMed: 36989470]

27.

Morrison A, Levy R. Fraction of nursing home admissions attributable to urinary incontinence. Value Health. 2006 Jul-Aug;9(4):272-4. [PubMed: 16903997]

28.

Ballstaedt L, Leslie SW, Woodbury B. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Feb 28, 2024. Bladder Post Void Residual Volume. [PubMed: 30969661]

29.

Pal M, Halder A, Bandyopadhyay S. Approach to a woman with urinary incontinence. Urol Ann. 2020 Jan-Mar;12(1):4-8. [PMC free article: PMC6978964] [PubMed: 32015609]

30.

Robledo D, Zuluaga L, Bravo-Balado A, Domínguez C, Trujillo CG, Caicedo JI, Rondón M, Azuero J, Plata M. Present value of the Urethral mobility test as a tool to assess Stress urinary incontinence due to Intrinsic sphincteric deficiency. Sci Rep. 2020 Dec 02;10(1):20993. [PMC free article: PMC7710709] [PubMed: 33268806]

31.

Bright E, Drake MJ, Abrams P. Urinary diaries: evidence for the development and validation of diary content, format, and duration. Neurourol Urodyn. 2011 Mar;30(3):348-52. [PubMed: 21284023]

32.

Bryan NP, Chapple CR. Frequency volume charts in the assessment and evaluation of treatment: how should we use them? Eur Urol. 2004 Nov;46(5):636-40. [PubMed: 15474275]

33.

Abrams P, Klevmark B. Frequency volume charts: an indispensable part of lower urinary tract assessment. Scand J Urol Nephrol Suppl. 1996;179:47-53. [PubMed: 8908664]

34.

Brown HW, Guan W, Schmuhl NB, Smith PD, Whitehead WE, Rogers RG. If We Don't Ask, They Won't Tell: Screening for Urinary and Fecal Incontinence by Primary Care Providers. J Am Board Fam Med. 2018 Sep-Oct;31(5):774-782. [PMC free article: PMC6170156] [PubMed: 30201674]

35.

Game X, Dmochowski R, Robinson D. Mixed urinary incontinence: Are there effective treatments? Neurourol Urodyn. 2023 Feb;42(2):401-408. [PMC free article: PMC10092712] [PubMed: 36762411]

36.

Huang YC, Chang KV. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 1, 2023. Kegel Exercises. [PubMed: 32310358]

37.

Azadzoi KM, Pontari M, Vlachiotis J, Siroky MB. Canine bladder blood flow and oxygenation: changes induced by filling, contraction and outlet obstruction. J Urol. 1996 Apr;155(4):1459-65. [PubMed: 8632611]

38.

Harrison SC, Ferguson DR, Doyle PT. Effect of bladder outflow obstruction on the innervation of the rabbit urinary bladder. Br J Urol. 1990 Oct;66(4):372-9. [PubMed: 1699626]

39.

van Koeveringe GA, Mostwin JL, van Mastrigt R, van Koeveringe BJ. Effect of partial urethral obstruction on force development of the guinea pig bladder. Neurourol Urodyn. 1993;12(6):555-66; discussion 566-71. [PubMed: 8312940]

40.

Seki N, Karim OM, Mostwin JL. The effect of experimental urethral obstruction and its reversal on changes in passive electrical properties of detrusor muscle. J Urol. 1992 Dec;148(6):1957-61. [PubMed: 1331551]

41.

DeLancey JO. Structural support of the urethra as it relates to stress urinary incontinence: the hammock hypothesis. Am J Obstet Gynecol. 1994 Jun;170(6):1713-20; discussion 1720-3. [PubMed: 8203431]

42.

Lukacz ES, Lawrence JM, Contreras R, Nager CW, Luber KM. Parity, mode of delivery, and pelvic floor disorders. Obstet Gynecol. 2006 Jun;107(6):1253-60. [PubMed: 16738149]

43.

Subak LL, Richter HE, Hunskaar S. Obesity and urinary incontinence: epidemiology and clinical research update. J Urol. 2009 Dec;182(6 Suppl):S2-7. [PMC free article: PMC2866035] [PubMed: 19846133]

44.

Hannestad YS, Lie RT, Rortveit G, Hunskaar S. Familial risk of urinary incontinence in women: population based cross sectional study. BMJ. 2004 Oct 16;329(7471):889-91. [PMC free article: PMC523112] [PubMed: 15485965]

45.

Elia G, Bergman J, Dye TD. Familial incidence of urinary incontinence. Am J Obstet Gynecol. 2002 Jul;187(1):53-5. [PubMed: 12114888]

46.

Subak LL, Wing R, West DS, Franklin F, Vittinghoff E, Creasman JM, Richter HE, Myers D, Burgio KL, Gorin AA, Macer J, Kusek JW, Grady D., PRIDE Investigators. Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med. 2009 Jan 29;360(5):481-90. [PMC free article: PMC2877497] [PubMed: 19179316]

47.

Rortveit G, Hannestad YS, Daltveit AK, Hunskaar S. Age- and type-dependent effects of parity on urinary incontinence: the Norwegian EPINCONT study. Obstet Gynecol. 2001 Dec;98(6):1004-10. [PubMed: 11755545]

48.

Managing acute and chronic urinary incontinence. AHCPR Urinary Incontinence in Adults Guideline Update Panel. Am Fam Physician. 1996 Oct;54(5):1661-72. [PubMed: 8857788]

49.

Dooley Y, Kenton K, Cao G, Luke A, Durazo-Arvizu R, Kramer H, Brubaker L. Urinary incontinence prevalence: results from the National Health and Nutrition Examination Survey. J Urol. 2008 Feb;179(2):656-61. [PubMed: 18082211]

50.

Carls C. The prevalence of stress urinary incontinence in high school and college-age female athletes in the midwest: implications for education and prevention. Urol Nurs. 2007 Feb;27(1):21-4, 39. [PubMed: 17390923]

51.

Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011 Oct;108(7):1132-8. [PubMed: 21231991]

52.

Khandelwal C, Kistler C. Diagnosis of urinary incontinence. Am Fam Physician. 2013 Apr 15;87(8):543-50. [PubMed: 23668444]

53.

Thomas-White KJ, Hilt EE, Fok C, Pearce MM, Mueller ER, Kliethermes S, Jacobs K, Zilliox MJ, Brincat C, Price TK, Kuffel G, Schreckenberger P, Gai X, Brubaker L, Wolfe AJ. Incontinence medication response relates to the female urinary microbiota. Int Urogynecol J. 2016 May;27(5):723-33. [PMC free article: PMC5119460] [PubMed: 26423260]

54.

Pearce MM, Hilt EE, Rosenfeld AB, Zilliox MJ, Thomas-White K, Fok C, Kliethermes S, Schreckenberger PC, Brubaker L, Gai X, Wolfe AJ. The female urinary microbiome: a comparison of women with and without urgency urinary incontinence. mBio. 2014 Jul 08;5(4):e01283-14. [PMC free article: PMC4161260] [PubMed: 25006228]

55.

Taweel WA, Seyam R. Neurogenic bladder in spinal cord injury patients. Res Rep Urol. 2015;7:85-99. [PMC free article: PMC4467746] [PubMed: 26090342]

56.

Nygaard I. Clinical practice. Idiopathic urgency urinary incontinence. N Engl J Med. 2010 Sep 16;363(12):1156-62. [PubMed: 20843250]

57.

Aoki Y, Brown HW, Brubaker L, Cornu JN, Daly JO, Cartwright R. Urinary incontinence in women. Nat Rev Dis Primers. 2017 Jul 06;3:17042. [PMC free article: PMC5878864] [PubMed: 28681849]

58.

Stewart F, Gameiro LF, El Dib R, Gameiro MO, Kapoor A, Amaro JL. Electrical stimulation with non-implanted electrodes for overactive bladder in adults. Cochrane Database Syst Rev. 2016 Dec 09;12(12):CD010098. [PMC free article: PMC6463833] [PubMed: 27935011]

59.

Committee Opinion No. 603: Evaluation of uncomplicated stress urinary incontinence in women before surgical treatment. Obstet Gynecol. 2014 Jun;123(6):1403-1407. [PubMed: 24848922]

60.

Holroyd-Leduc JM, Tannenbaum C, Thorpe KE, Straus SE. What type of urinary incontinence does this woman have? JAMA. 2008 Mar 26;299(12):1446-56. [PubMed: 18364487]

61.

Harvey MA, Versi E. Predictive value of clinical evaluation of stress urinary incontinence: a summary of the published literature. Int Urogynecol J Pelvic Floor Dysfunct. 2001;12(1):31-7. [PubMed: 11294529]

62.

Winters JC, Dmochowski RR, Goldman HB, Herndon CD, Kobashi KC, Kraus SR, Lemack GE, Nitti VW, Rovner ES, Wein AJ., American Urological Association. Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction. Urodynamic studies in adults: AUA/SUFU guideline. J Urol. 2012 Dec;188(6 Suppl):2464-72. [PubMed: 23098783]

63.

Milleman M, Langenstroer P, Guralnick ML. Post-void residual urine volume in women with overactive bladder symptoms. J Urol. 2004 Nov;172(5 Pt 1):1911-4. [PubMed: 15540753]

64.

Wyman JF, Choi SC, Harkins SW, Wilson MS, Fantl JA. The urinary diary in evaluation of incontinent women: a test-retest analysis. Obstet Gynecol. 1988 Jun;71(6 Pt 1):812-7. [PubMed: 3368165]

65.

Homma Y, Ando T, Yoshida M, Kageyama S, Takei M, Kimoto K, Ishizuka O, Gotoh M, Hashimoto T. Voiding and incontinence frequencies: variability of diary data and required diary length. Neurourol Urodyn. 2002;21(3):204-9. [PubMed: 11948713]

66.

Mehta S, Geng B, Xu X, Harmanli O. Current state of bladder diary: a survey and review of the literature. Int Urogynecol J. 2023 Apr;34(4):809-823. [PubMed: 36322174]

67.

Nambiar AK, Arlandis S, Bø K, Cobussen-Boekhorst H, Costantini E, de Heide M, Farag F, Groen J, Karavitakis M, Lapitan MC, Manso M, Arteaga SM, Riogh ANA, O'Connor E, Omar MI, Peyronnet B, Phé V, Sakalis VI, Sihra N, Tzelves L, van Poelgeest-Pomfret ML, van den Bos TWL, van der Vaart H, Harding CK. European Association of Urology Guidelines on the Diagnosis and Management of Female Non-neurogenic Lower Urinary Tract Symptoms. Part 1: Diagnostics, Overactive Bladder, Stress Urinary Incontinence, and Mixed Urinary Incontinence. Eur Urol. 2022 Jul;82(1):49-59. [PubMed: 35216856]

68.

Espuña-Pons M, Diez-Itza I, Anglès-Acedo S, Covernton PJO., GISPEM group. Cough stress tests to diagnose stress urinary incontinence in women with pelvic organ prolapse with indication for surgical treatment. Neurourol Urodyn. 2020 Feb;39(2):819-825. [PMC free article: PMC7078860] [PubMed: 32040873]

69.

Long CY, Loo ZX, Wu CH, Lin KL, Yeh CL, Feng CW, Wu PC. Relationship between Q-Tip Test and Urethral Hypermobility on Perineal Ultrasound. J Clin Med. 2023 Jul 24;12(14) [PMC free article: PMC10381566] [PubMed: 37510978]

70.

Wu CJ, Ting WH, Lin HH, Hsiao SM. Clinical and Urodynamic Predictors of the Q-Tip Test in Women With Lower Urinary Tract Symptoms. Int Neurourol J. 2020 Mar;24(1):52-58. [PMC free article: PMC7136438] [PubMed: 32252186]

71.

Jha S, Jeppson PC, Dokmeci F, Marquini GV, Sartori MGF, Moalli P, Malik SA. Management of mixed urinary incontinence: IUGA committee opinion. Int Urogynecol J. 2024 Feb;35(2):291-301. [PMC free article: PMC10908639] [PubMed: 38252279]

72.

Hu Y, Lou Y, Liao L, Xu M, Zhang H, Yang Q, Wu H. Comparison of Urodynamics and Perineal Ultrasonography for the Diagnosis of Mixed Urinary Incontinence in Women. J Ultrasound Med. 2018 Nov;37(11):2647-2656. [PubMed: 29608019]

73.

Collins CW, Winters JC., American Urological Association. Society of Urodynamics Female Pelvic Medicine and Urogenital Reconstruction. AUA/SUFU adult urodynamics guideline: a clinical review. Urol Clin North Am. 2014 Aug;41(3):353-62, vii. [PubMed: 25063591]

74.

Sinha S, Lakhani D, Singh VP. Cough associated detrusor overactivity in women with urinary incontinence. Neurourol Urodyn. 2019 Mar;38(3):920-926. [PubMed: 30742327]

75.

Rosier PF, Gajewski JB, Sand PK, Szabó L, Capewell A, Hosker GL., International Consultation on Incontinence 2008 Committee on Dynamic Testing. Executive summary: The International Consultation on Incontinence 2008--Committee on: "Dynamic Testing"; for urinary incontinence and for fecal incontinence. Part 1: Innovations in urodynamic techniques and urodynamic testing for signs and symptoms of urinary incontinence in female patients. Neurourol Urodyn. 2010;29(1):140-5. [PubMed: 19693949]

76.

Yao M, Simoes A. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 14, 2023. Urodynamic Testing and Interpretation. [PubMed: 32965981]

77.

Tabei SS, Baas W, Mahdy A. Pharmacotherapy in Stress Urinary Incontinence; A Literature Review. Curr Urol Rep. 2024 Jul;25(7):141-148. [PMC free article: PMC11196290] [PubMed: 38727982]

78.

Strojek K, Strączyńska A, Radzimińska A, Weber-Rajek M. The Effects of Extracorporeal Magnetic Innervation in the Treatment of Women with Urinary Incontinence: A Systematic Review. J Clin Med. 2023 Aug 22;12(17) [PMC free article: PMC10487770] [PubMed: 37685522]

79.

Bai J, Tian Y, Wang Y, Zhang X, Wang P. Physical and Rehabilitation Therapy for Overactive Bladder in Women: A Systematic Review and Meta-Analysis. Int J Clin Pract. 2023;2023:6758454. [PMC free article: PMC9833926] [PubMed: 36704247]

80.

Yin Y, Zhao C, Liu M, Chen J. Effect of Electroacupuncture Combined with Pelvic Floor Muscle Exercise on Urinary Symptoms, Sexual Dysfunction and Pelvic Floor Muscle Strength in Female Patients with Overactive Bladder: A Retrospective Study. Arch Esp Urol. 2024 Apr;77(3):256-262. [PubMed: 38715166]

81.

Wenming C, Xiaoman D, Ling G, Yun L, Xiyan G. Acupuncture combined with pelvic floor rehabilitation training for postpartum stress urinary incontinence: protocol for a systematic review and meta-analysis. Front Med (Lausanne). 2023;10:1296751. [PMC free article: PMC10730657] [PubMed: 38126072]

82.

Long Z, Chen H, Yu S, Wang X, Liu Z. Effect of Acupuncture for Mixed Urinary Incontinence in Women: A Systematic Review. Front Public Health. 2022;10:827853. [PMC free article: PMC8971660] [PubMed: 35372235]

83.

Hargreaves E, Baker K, Barry G, Harding C, Zhang Y, Kandala NB, Zhang X, Kernohan A, Clarkson CE. Acupuncture for treating overactive bladder in adults. Cochrane Database Syst Rev. 2022 Sep 23;9(9):CD013519. [PMC free article: PMC9502659] [PubMed: 36148895]

84.

Urinary incontinence and pelvic organ prolapse in women: management. National Institute for Health and Care Excellence (NICE); London: Jun, 2019. [PubMed: 31211537]

85.

Funada S, Yoshioka T, Luo Y, Sato A, Akamatsu S, Watanabe N. Bladder training for treating overactive bladder in adults. Cochrane Database Syst Rev. 2023 Oct 09;10(10):CD013571. [PMC free article: PMC10561149] [PubMed: 37811598]

86.

Gordon B. Nutritional Considerations for Bladder Storage Conditions in Adult Females. Int J Environ Res Public Health. 2023 Oct 03;20(19) [PMC free article: PMC10573006] [PubMed: 37835149]

87.

Balk EM, Rofeberg VN, Adam GP, Kimmel HJ, Trikalinos TA, Jeppson PC. Pharmacologic and Nonpharmacologic Treatments for Urinary Incontinence in Women: A Systematic Review and Network Meta-analysis of Clinical Outcomes. Ann Intern Med. 2019 Apr 02;170(7):465-479. [PubMed: 30884526]

88.

Nambiar AK, Bosch R, Cruz F, Lemack GE, Thiruchelvam N, Tubaro A, Bedretdinova DA, Ambühl D, Farag F, Lombardo R, Schneider MP, Burkhard FC. EAU Guidelines on Assessment and Nonsurgical Management of Urinary Incontinence. Eur Urol. 2018 Apr;73(4):596-609. [PubMed: 29398262]

89.

Dufour S, Wu M. No. 397 - Conservative Care of Urinary Incontinence in Women. J Obstet Gynaecol Can. 2020 Apr;42(4):510-522. [PubMed: 32303295]

90.

Miller JM, Hawthorne KM, Park L, Tolbert M, Bies K, Garcia C, Misiunas R, Newhouse W, Smith AR. Self-Perceived Improvement in Bladder Health After Viewing a Novel Tutorial on Knack Use: A Randomized Controlled Trial Pilot Study. J Womens Health (Larchmt). 2020 Oct;29(10):1319-1327. [PMC free article: PMC7583334] [PubMed: 31800360]

91.

Miller JM, Ashton-Miller JA, Delancey JO. Quantification of cough-related urine loss using the paper towel test. Obstet Gynecol. 1998 May;91(5 Pt 1):705-9. [PubMed: 9572215]

92.

Miller JM, Umek WH, Delancey JO, Ashton-Miller JA. Can women without visible pubococcygeal muscle in MR images still increase urethral closure pressures? Am J Obstet Gynecol. 2004 Jul;191(1):171-5. [PubMed: 15295360]

93.

Mayer R, Wells TJ, Brink CA, Clark P. Correlations between dynamic urethral profilometry and perivaginal pelvic muscle activity. Neurourol Urodyn. 1994;13(3):227-35. [PubMed: 7920679]

94.

Miller JM, Perucchini D, Carchidi LT, DeLancey JO, Ashton-Miller J. Pelvic floor muscle contraction during a cough and decreased vesical neck mobility. Obstet Gynecol. 2001 Feb;97(2):255-60. [PMC free article: PMC1226460] [PubMed: 11165591]

95.

Burgio KL, Goode PS, Locher JL, Umlauf MG, Roth DL, Richter HE, Varner RE, Lloyd LK. Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial. JAMA. 2002 Nov 13;288(18):2293-9. [PubMed: 12425706]

96.

Lúcio A, Lourenço CB, Damasceno BP, de Moraes Lopes MHB, Dʼancona CAL. The Effect of Pelvic Floor Muscle Contraction on Detrusor Overactivity Pressure in Neurogenic and Nonneurogenic Women During Urodynamic Study: A Cross-Sectional Study. Am J Phys Med Rehabil. 2019 Apr;98(4):275-279. [PubMed: 30893073]

97.

Zubieta M, Carr RL, Drake MJ, Bø K. Influence of voluntary pelvic floor muscle contraction and pelvic floor muscle training on urethral closure pressures: a systematic literature review. Int Urogynecol J. 2016 May;27(5):687-96. [PubMed: 26407561]

98.

Brækken IH, Villumstad TKLS, Evensen NM. Randomised controlled pilot trial to assess effect of electrical stimulation of weak pelvic floor muscles. Arch Gynecol Obstet. 2024 Jun;309(6):2921-2929. [PMC free article: PMC11147843] [PubMed: 38551705]

99.

Liao L, Li X, Chong T, Chen Q, Xu Z, Huang B, Chen M, Li H, Wei Z, Shao Y, Lu J, Pang R, Li X, Wang Y. Efficacy and safety of tibial nerve stimulation using a wearable device for overactive bladder. BJU Int. 2024 Jun;133(6):760-769. [PubMed: 38468422]

100.

Barba M, Cola A, Rezzan G, Costa C, Re I, Volontè S, Terzoni S, Frigerio M, Maruccia S. Flat Magnetic Stimulation for Urge Urinary Incontinence. Medicina (Kaunas). 2023 Nov 14;59(11) [PMC free article: PMC10673601] [PubMed: 38004048]

101.

Ghaderi F, Kharaji G, Hajebrahimi S, Pashazadeh F, Berghmans B, Pourmehr HS. Physiotherapy in Patients with Stress Urinary Incontinence: A Systematic Review and Meta-analysis. Urol Res Pract. 2023 Sep;49(5):293-306. [PMC free article: PMC10646808] [PubMed: 37877877]

102.

Gumussoy S, Kavlak O, Yeniel AO. Effects of Biofeedback-Guided Pelvic Floor Muscle Training With and Without Extracorporeal Magnetic Innervation Therapy on Stress Incontinence: A Randomized Controlled Trial. 2021 Mar-Apr 01J Wound Ostomy Continence Nurs. 48(2):153-161. [PubMed: 33690249]

103.

Weber-Rajek M, Strączyńska A, Strojek K, Piekorz Z, Pilarska B, Podhorecka M, Sobieralska-Michalak K, Goch A, Radzimińska A. Assessment of the Effectiveness of Pelvic Floor Muscle Training (PFMT) and Extracorporeal Magnetic Innervation (ExMI) in Treatment of Stress Urinary Incontinence in Women: A Randomized Controlled Trial. Biomed Res Int. 2020;2020:1019872. [PMC free article: PMC6988664] [PubMed: 32016111]

104.

Hoşcan MB, Dilmen C, Perk H, Soyupek S, Armağan A, Tükel O, Ekinci M. Extracorporeal magnetic innervation for the treatment of stress urinary incontinence: results of two-year follow-up. Urol Int. 2008;81(2):167-72. [PubMed: 18758214]

105.

Huang J, Fan Y, Wang D, Deng Q, Zou X, Yu J. Efficacy and safety of vaginal electrical stimulation as an alternative or adjunct treatment for overactive bladder syndrome in women: a meta-analysis of randomized controlled trials. Int Urogynecol J. 2023 Oct;34(10):2345-2357. [PubMed: 37368020]

106.

Burton CS, Korsandi S, Enemchukwu E. Current State of Non-surgical Devices for Female Stress Urinary Incontinence. Curr Urol Rep. 2022 Sep;23(9):185-194. [PubMed: 35997889]

107.

Funada S, Luo Y, Uozumi R, Watanabe N, Goto T, Negoro H, Ueno K, Ichioka K, Segawa T, Akechi T, Ogawa O, Akamatsu S, Kobayashi T, Furukawa TA. Multicomponent Intervention for Overactive Bladder in Women: A Randomized Clinical Trial. JAMA Netw Open. 2024 Mar 04;7(3):e241784. [PMC free article: PMC10938174] [PubMed: 38477920]

108.

Scaldazza CV, Morosetti C, Giampieretti R, Lorenzetti R, Baroni M. Percutaneous tibial nerve stimulation versus electrical stimulation with pelvic floor muscle training for overactive bladder syndrome in women: results of a randomized controlled study. Int Braz J Urol. 2017 Jan-Feb;43(1):121-126. [PMC free article: PMC5293392] [PubMed: 28124534]

109.

Wang AC, Wang YY, Chen MC. Single-blind, randomized trial of pelvic floor muscle training, biofeedback-assisted pelvic floor muscle training, and electrical stimulation in the management of overactive bladder. Urology. 2004 Jan;63(1):61-6. [PubMed: 14751349]

110.

Ghossein N, Kang M, Lakhkar AD. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 8, 2023. Anticholinergic Medications. [PubMed: 32310353]

111.

Dawood O, El-Zawahry A. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 28, 2023. Mirabegron. [PubMed: 30860748]

112.

Dwyer J, Tafuri SM, LaGrange CA. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 17, 2023. Oxybutynin. [PubMed: 29763161]

113.

Narain S, Parmar M. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 23, 2023. Tolterodine. [PubMed: 32491781]

114.

Uhr A, Glick L, Barron S, Zavodnick J, Mark JR, Shenot P, Murphy A. How I Do It: PureWick female external catheter: a non-invasive urine management system for incontinent women. Can J Urol. 2021 Jun;28(3):10669-10672. [PubMed: 34129459]

115.

Cilluffo S, Terzoni S, Destrebecq A, Lusignani M. Efficacy, effectiveness, usability and acceptability of devices for female urinary incontinence: A scoping review. J Clin Nurs. 2023 Jul;32(13-14):3361-3377. [PubMed: 35851974]

116.

Beeson T, Pittman J, Davis CR. Effectiveness of an External Urinary Device for Female Anatomy and Trends in Catheter-Associated Urinary Tract Infections. 2023 Mar-Apr 01J Wound Ostomy Continence Nurs. 50(2):137-141. [PMC free article: PMC9990593] [PubMed: 36867037]

117.

Jasperse N, Hernandez-Dominguez O, Deyell JS, Prasad JP, Yuan C, Tomy M, Kuza CM, Grigorian A, Nahmias J. A single institution pre-/post-comparison after introduction of an external urinary collection device for female medical patients. J Infect Prev. 2022 Jul;23(4):149-154. [PMC free article: PMC10226054] [PubMed: 37256156]

118.

Khosla L, Sani JM, Chughtai B. Patient and caretaker satisfaction with the PureWick system. Can J Urol. 2022 Aug;29(4):11216-11223. [PubMed: 35969725]

119.

Bagley K, Severud L. Preventing Catheter-Associated Urinary Tract Infections with Incontinence Management Alternatives: PureWick and Condom Catheter. Nurs Clin North Am. 2021 Sep;56(3):413-425. [PubMed: 34366161]

120.

Al-Shaikh G, Syed S, Osman S, Bogis A, Al-Badr A. Pessary use in stress urinary incontinence: a review of advantages, complications, patient satisfaction, and quality of life. Int J Womens Health. 2018;10:195-201. [PMC free article: PMC5909791] [PubMed: 29713205]

121.

Nygaard I. Prevention of exercise incontinence with mechanical devices. J Reprod Med. 1995 Feb;40(2):89-94. [PubMed: 7738934]

122.

Wood LN, Anger JT. Urinary incontinence in women. BMJ. 2014 Sep 15;349:g4531. [PubMed: 25225003]

123.

Roehl B, Buchanan EM. Urinary incontinence evaluation and the utility of pessaries in older women. Care Manag J. 2006 Winter;7(4):213-7. [PubMed: 17194058]

124.

Komesu YM, Ketai LH, Rogers RG, Eberhardt SC, Pohl J. Restoration of continence by pessaries: magnetic resonance imaging assessment of mechanism of action. Am J Obstet Gynecol. 2008 May;198(5):563.e1-6. [PMC free article: PMC5477421] [PubMed: 18355780]

125.

Trowbridge ER, Fenner DE. Practicalities and pitfalls of pessaries in older women. Clin Obstet Gynecol. 2007 Sep;50(3):709-19. [PubMed: 17762419]

126.

Donnelly MJ, Powell-Morgan S, Olsen AL, Nygaard IE. Vaginal pessaries for the management of stress and mixed urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2004 Sep-Oct;15(5):302-7. [PubMed: 15300365]

127.

Subak LL, Quesenberry CP, Posner SF, Cattolica E, Soghikian K. The effect of behavioral therapy on urinary incontinence: a randomized controlled trial. Obstet Gynecol. 2002 Jul;100(1):72-8. [PubMed: 12100806]

128.

Lorzadeh N, Jahanshahi M. The effect of duloxetine on stress urinary incontinence. Health Sci Rep. 2024 May;7(5):e2091. [PMC free article: PMC11082090] [PubMed: 38736475]

129.

Shamliyan T, Wyman JF, Ramakrishnan R, Sainfort F, Kane RL. Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review. Ann Intern Med. 2012 Jun 19;156(12):861-74, W301-10. [PubMed: 22711079]

130.

Kreydin EI, Gomes CM, Cruz F. Current pharmacotherapy of overactive bladder. Int Braz J Urol. 2021 Nov-Dec;47(6):1091-1107. [PMC free article: PMC8486454] [PubMed: 34003613]

131.

Kornholt J, Sonne DP, Riis T, Sonne J, Klarskov N. Effect of imipramine on urethral opening pressure: A randomized, double-blind, placebo-controlled crossover study in healthy women. Neurourol Urodyn. 2019 Apr;38(4):1076-1080. [PubMed: 30843263]

132.

Tsakiris P, de la Rosette JJ, Michel MC, Oelke M. Pharmacologic treatment of male stress urinary incontinence: systematic review of the literature and levels of evidence. Eur Urol. 2008 Jan;53(1):53-9. [PubMed: 17920183]

133.

Dhaliwal JS, Spurling BC, Molla M. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 29, 2023. Duloxetine. [PubMed: 31747213]

134.

Kotecha P, Sahai A, Malde S. Use of Duloxetine for Postprostatectomy Stress Urinary Incontinence: A Systematic Review. Eur Urol Focus. 2021 May;7(3):618-628. [PubMed: 32605820]

135.

Hagovska M, Svihra J. Evaluation of duloxetine and innovative pelvic floor muscle training in women with stress urinary incontinence (DULOXING): Study protocol clinical trial (SPIRIT Compliant). Medicine (Baltimore). 2020 Feb;99(6):e18834. [PMC free article: PMC7015553] [PubMed: 32028393]

136.

Yono M, Otani M, Ito K, Inoue Y, Furukawa K, Hori M, Tsuji S, Tanaka T, Sakata Y, Irie S. Effect of Duloxetine on Urethral Resting Pressure and on Sphincter Contractility in Response to Coughing and Magnetic Stimulation in Healthy Women. Low Urin Tract Symptoms. 2015 May;7(2):93-8. [PubMed: 26663688]

137.

Maund E, Tendal B, Hróbjartsson A, Jørgensen KJ, Lundh A, Schroll J, Gøtzsche PC. Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications. BMJ. 2014 Jun 04;348:g3510. [PMC free article: PMC4045316] [PubMed: 24899650]

138.

Maund E, Guski LS, Gøtzsche PC. Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports. CMAJ. 2017 Feb 06;189(5):E194-E203. [PMC free article: PMC5289870] [PubMed: 28246265]

139.

Martins DO, Pinho M, Caldas F, Pereira EG. Visual Hallucinations After Duloxetine Use. Prim Care Companion CNS Disord. 2024 Jan 25;26(1) [PubMed: 38277643]

140.

Leslie SW, Sajjad H, Singh S. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Feb 17, 2024. Nocturia. [PubMed: 30085529]

141.

Feloney MP, Stauss K, Leslie SW. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Apr 18, 2024. Sacral Neuromodulation. [PubMed: 33620828]

142.

Lovatsis D, Easton W, Wilkie D. No. 248-Guidelines for the Evaluation and Treatment of Recurrent Urinary Incontinence Following Pelvic Floor Surgery. J Obstet Gynaecol Can. 2017 Sep;39(9):e309-e314. [PubMed: 28859774]

143.

Makajeva J, Watters C, Safioleas P. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Oct 17, 2022. Cystocele. [PubMed: 33231973]

144.

Ladd M, Tuma F. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 8, 2023. Rectocele. [PubMed: 31536295]

145.

Aboseif C, Liu P. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Oct 3, 2022. Pelvic Organ Prolapse. [PubMed: 33085376]

146.

Eisner H, McIntosh GV. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 14, 2023. Pubovaginal Sling. [PubMed: 34283516]

147.

Riggs JA. Retropubic cystourethropexy: a review of two operative procedures with long-term follow-up. Obstet Gynecol. 1986 Jul;68(1):98-105. [PubMed: 3523334]

148.

Chen CJ, Thompson H. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Oct 31, 2022. Uterine Prolapse. [PubMed: 33232087]

149.

Kim MS, Lee GH, Na ED, Jang JH, Kim HC. The association of pelvic organ prolapse severity and improvement in overactive bladder symptoms after surgery for pelvic organ prolapse. Obstet Gynecol Sci. 2016 May;59(3):214-9. [PMC free article: PMC4871938] [PubMed: 27200312]

150.

Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, Monga A, Petri E, Rizk DE, Sand PK, Schaer GN. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010 Jan;21(1):5-26. [PubMed: 19937315]

151.

Basu M, Duckett J. Effect of prolapse repair on voiding and the relationship to overactive bladder and detrusor overactivity. Int Urogynecol J Pelvic Floor Dysfunct. 2009 May;20(5):499-504. [PubMed: 19214362]

152.

Ozkurkcugil C, Avci IE. Factors predicting treatment success in mixed urinary incontinence treated with midurethral sling. Low Urin Tract Symptoms. 2023 Mar;15(2):50-56. [PubMed: 36535743]

153.

Nash S, Aboseif S, Gilling P, Gretzer M, Samowitz H, Rose M, Slutsky J, Siegel S, Tu LM. Treatment with an adjustable long-term implant for post-prostatectomy stress incontinence: The ProACT™ pivotal trial. Neurourol Urodyn. 2018 Nov;37(8):2854-2859. [PubMed: 30178536]

154.

Klock JA, Palacios AR, Leslie SW, Feloney MP. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Nov 2, 2023. Artificial Urinary Sphincters and Adjustable Dual-Balloon Continence Therapy in Men. [PubMed: 37983344]

155.

Kong L, Coddington ND, Flynn BJ. Secondary placement of adjustable continence therapy (ProACT™) using open perineal technique: Case report of ProACT placement in a man with a devastated urethra following pelvic trauma and multiple AUS erosions. Urol Case Rep. 2023 Jul;49:102424. [PMC free article: PMC10276208] [PubMed: 37334261]

156.

Ruggiero M, Pinar U, Popelin MB, Rod X, Denys P, Bazinet A, Chartier-Kastler E. Single center experience and long-term outcomes of implantable devices ACT and Pro-ACT (Uromedica, Irvin, CA, USA) - Adjustable continence Therapy for treatment of stress urinary incontinence. Prog Urol. 2023 Feb;33(2):96-102. [PubMed: 36572628]

157.

Munier P, Nicolas M, Tricard T, Droupy S, Costa P, Saussine C. What if artificial urinary sphincter is not possible? Feasibility and effectiveness of ProACT for patients with persistent stress urinary incontinence after radical prostatectomy treated by sling. Neurourol Urodyn. 2020 Jun;39(5):1417-1422. [PubMed: 32249971]

158.

Téllez C, Szczesniewski J, Virseda-Chamorro M, Arance I, Angulo JC. Update on Adjustable Trans-Obturator Male System (ATOMS) for Male Incontinence after Prostate Cancer Surgery. Curr Oncol. 2023 Apr 12;30(4):4153-4165. [PMC free article: PMC10136884] [PubMed: 37185429]

159.

de Guerry ML, Demeestere A, Bergot C, de Hauteclocque A, Hascoet J, Bajeot AS, Ternynck C, Gamé X, Peyronnet B, Capon G, Perrouin-Verbe MA, Biardeau X. Adjustable Continence Therapy (ACT®) balloons to treat female stress urinary incontinence: effectiveness, safety and risk factors of failure and complication. Int Urogynecol J. 2023 Apr;34(4):877-883. [PubMed: 35751672]

160.

Smith WJ, VanDyke ME, Venishetty N, Langford BT, Franzen BP, Morey AF. Surgical Management of Male Stress Incontinence: Techniques, Indications, and Pearls for Success. Res Rep Urol. 2023;15:217-232. [PMC free article: PMC10290851] [PubMed: 37366389]

161.

Salciccia S, Viscuso P, Bevilacqua G, Tufano A, Casale P, De Berardinis E, Di Pierro GB, Cattarino S, Gentilucci A, Lourdes Lia F, Ivan DG, Rosati D, Del Giudice F, Sciarra A, Mariotti G. Comparison of Different Invasive Devices for the Treatment of Urinary Incontinence after Radical Prostatectomy. Adv Urol. 2022;2022:8736249. [PMC free article: PMC9239822] [PubMed: 35774194]

162.

Ricard H, Léon G, Branchereau J, Bouchot O, Karam G, Le Normand L, Rigaud J, Perrouin-Verbe MA. Adjustable continence balloons in postprostatectomy incontinence: Outcomes and complications. Neurourol Urodyn. 2022 Aug;41(6):1414-1422. [PubMed: 35686550]

163.

Demeestere A, de Guerry ML, Bergot C, de Hauteclocque A, Hascoet J, Gamé X, Bajeot AS, Peyronnet B, Capon G, Perrouin-Verbe MA, Biardeau X. Adjustable continence therapy (ACT®) balloons to treat neurogenic and non-neurogenic female urinary incontinence. Neurourol Urodyn. 2022 Jan;41(1):313-322. [PubMed: 34633672]

164.

Kaboré FA, Gaillet S, Blanc J, Boissier R, Aurier KL, Delaporte V, Coulange C, Lechevallier E, Karsenty G. [Initial results of adjustable periurethral balloons (ACT™ and pro ACT™) in the treatment of adult stress urinary incontinence with intrinsic sphincter deficiency]. Prog Urol. 2014 Dec;24(17):1132-8. [PubMed: 25217479]

165.

Billault C, Chartier-Kastler E, Rouprêt M, Robain G, Phé V. Functional outcomes of adjustable continence therapy (ACT™) balloons in women aged >80 years and suffering from stress urinary incontinence caused by intrinsic sphincter deficiency. World J Urol. 2015 Nov;33(11):1897-903. [PubMed: 25701129]

166.

Peyronnet B, Greenwell T, Gray G, Khavari R, Thiruchelvam N, Capon G, Ockrim J, Lopez-Fando L, Gilleran J, Fournier G, Van Koeveringe GA, Van Der Aa F. Current Use of the Artificial Urinary Sphincter in Adult Females. Curr Urol Rep. 2020 Oct 24;21(12):53. [PubMed: 33098485]

167.

Denormandie A, Chartier-Kastler E, Haddad R, Robain G, Guillot-Tantay C, Phé V. Long-term functional outcomes of artificial urinary sphincter (AMS 800™) implantation in women aged over 75 years and suffering from stress urinary incontinence caused by intrinsic sphincter deficiency. World J Urol. 2021 Oct;39(10):3897-3902. [PubMed: 33938979]

168.

Schroeder A, Munier P, Saussine C, Tricard T. Outcomes of laparoscopic artificial urinary sphincter in women with stress urinary incontinence: mid-term evaluation. World J Urol. 2021 Aug;39(8):3057-3062. [PubMed: 33388876]

169.

Tricard T, Al Hashimi I, Schroeder A, Munier P, Saussine C. Real-life outcomes after artificial urinary sphincter explantation in women suffering from severe stress incontinence. World J Urol. 2021 Oct;39(10):3891-3896. [PubMed: 33835209]

170.

Barakat B, Franke K, Hijazi S, Schakaki S, Gauger U, Hasselhof V, Vögeli TA. A systematic review and meta-analysis of clinical and functional outcomes of artificial urinary sphincter implantation in women with stress urinary incontinence. Arab J Urol. 2020 Feb 04;18(2):78-87. [PMC free article: PMC7473178] [PubMed: 33029411]

171.

Peyronnet B, O'Connor E, Khavari R, Capon G, Manunta A, Allue M, Hascoet J, Nitti VW, Gamé X, Gilleran J, Castro-Sader L, Cornu JN, Waltregny D, Ahyai S, Chung E, Elliott DS, Fournier G, Brucker BM. AMS-800 Artificial urinary sphincter in female patients with stress urinary incontinence: A systematic review. Neurourol Urodyn. 2019 Aug;38 Suppl 4:S28-S41. [PubMed: 30298943]

172.

Chung E, Liao L, Kim JH, Wang Z, Kitta T, Lin AT, Lee KS, Ye L, Chu P, Kaiho Y, Takei M, Jiang H, Lee J, Masuda H, Tse V. The Asia-Pacific AMS800 artificial urinary sphincter consensus statement. Int J Urol. 2023 Feb;30(2):128-138. [PMC free article: PMC10100264] [PubMed: 36375037]

173.

Shokri P, Kharaz L, Talebian N, Borumandnia N, Ziaee SAM, Shakhssalim N. A systematic review and meta-analysis of complications of artificial urinary sphincters in female patients with urinary incontinence due to internal sphincter insufficiency. BMC Urol. 2023 May 20;23(1):97. [PMC free article: PMC10200041] [PubMed: 37210489]

174.

Ferreira C, Brychaert PE, Menard J, Mandron E. Laparoscopic implantation of artificial urinary sphincter in women with intrinsic sphincter deficiency: Mid-term outcomes. Int J Urol. 2017 Apr;24(4):308-313. [PubMed: 28215049]

175.

Peyronnet B, Gray G, Capon G, Cornu JN, Van Der Aa F. Robot-assisted artificial urinary sphincter implantation. Curr Opin Urol. 2021 Jan;31(1):2-10. [PubMed: 33239514]

176.

Carson CC. Artificial urinary sphincter: current status and future directions. Asian J Androl. 2020 Mar-Apr;22(2):154-157. [PMC free article: PMC7155799] [PubMed: 32129191]

177.

Lim YN, Dwyer PL. Effectiveness of midurethral slings in intrinsic sphincteric-related stress urinary incontinence. Curr Opin Obstet Gynecol. 2009 Oct;21(5):428-33. [PubMed: 19593133]

178.

Schierlitz L, Dwyer PL, Rosamilia A, Murray C, Thomas E, De Souza A, Lim YN, Hiscock R. Effectiveness of tension-free vaginal tape compared with transobturator tape in women with stress urinary incontinence and intrinsic sphincter deficiency: a randomized controlled trial. Obstet Gynecol. 2008 Dec;112(6):1253-1261. [PubMed: 19037033]

179.

Shah SM, Gaunay GS. Treatment options for intrinsic sphincter deficiency. Nat Rev Urol. 2012 Nov;9(11):638-51. [PubMed: 23027065]

180.

Guérin S, Khene ZE, Peyronnet B. Adjustable Continence Therapy Balloons in Female Patients with Stress Urinary Incontinence: A Systematic Review. Urol Int. 2023;107(7):653-665. [PubMed: 37271125]

181.

Freton L, Tondut L, Enderle I, Hascoet J, Manunta A, Peyronnet B. Comparison of adjustable continence therapy periurethral balloons and artificial urinary sphincter in female patients with stress urinary incontinence due to intrinsic sphincter deficiency. Int Urogynecol J. 2018 Jul;29(7):949-957. [PubMed: 29332254]

182.

Lee CL, Park JM, Lee JY, Yang SW, Na HS, Lee J, Jung S, Shin JH. A Novel Incisionless Disposable Vaginal Device for Female Stress Urinary Incontinence: Efficacy and Quality of Life. Int Neurourol J. 2023 May;27(Suppl 1):S40-48. [PMC free article: PMC10263161] [PubMed: 37280759]

183.

McConnell EA. Applying a condom catheter. Nursing. 2001 Jan;31(1):70. [PubMed: 11216249]

Disclosure: Shauna Harris declares no relevant financial relationships with ineligible companies.

Disclosure: Stephen Leslie declares no relevant financial relationships with ineligible companies.

Disclosure: John Riggs declares no relevant financial relationships with ineligible companies.